Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eleven groups of workers submitted a total of 21 bronchial tumour-associated antigen preparations and 19 antisera for comparative studies. Many of the antisera proved to be polyspecific despite absorption procedures. Most of the antigen preparations contained some material reactive towards a reference antiserum to normal human serum proteins. While it appeared that no participants were studying identical antigen-antibody reactions, several cross-reactivities were identified in the antisera. When immune reactions to CEA, AFP, NCA, ferritin, lactoferrin, human pepsin and gastricsin, and the pregnancy proteins, SP1 and SP3 were excluded by use of reference antisera and electroimmunoprecipitation methods, there remained 5 antigen-antibody reactions defining unique antigens. The clinical usefulness of any of these 5 antigens has yet to be determined.
 ...
PMID:Collaborative study of bronchial tumour-associated antigens. 617 Mar

Serial measurements of serum ferritin have been assessed as an additional marker in a study of 12 patients with germ cell tumours. The standard markers, serum AFP and beta HCG, were also assessed serially. During treatment elevated levels of serum ferritin were detected in 10 patients, elevated AFP in 10 patients and elevated beta HCG in 6 patients. A poor prognosis was associated with persistently raised serum ferritin and either, or both, elevated AFP and beta HCG levels. Decreasing levels of serum ferritin indicated favourable response to treatment; rising values were associated with recurrence or dissemination of tumour. Even if serum ferritin cannot be classed specifically as a tumour product, it may be useful in the early detection of residual or recurrent tumour.
 ...
PMID:Serum ferritin as a third marker in germ cell tumours. 617 93

Screening for pancreatic cancer was carried out by serum pancreatic oncofetal antigen (POA) tests in 440 out-patients with abdominal complaints, with concomitant assay of carcinoembryonic antigen, alpha-fetoprotein and ferritin. POA was positive in 13 patients, of whom 3 cases of pancreatic cancer, and 4 of other malignant diseases were diagnosed while the remaining 6 were non-malignant. Of these out-patients, 5 cases were finally diagnosed as having pancreatic cancer by further examinations. Of these 5 patients, POA was negative in 2, of whom one was positive for CEA and AFP. Accordingly, when POA test was applied concomitantly with the other 3 marker tests, the detection rate of pancreatic cancer was elevated to 4/5. Twenty-three patients were found to have malignant diseases and 20 of them were positive for at least one of the 4 markers tested. These results suggest that serum POA assay is useful for screening the pancreatic cancer, especially when the other tumor markers are assayed concomitantly.
 ...
PMID:Serum pancreatic oncofetal antigen: its clinical usefulness for screening pancreatic cancer in combination with tests for other tumor markers. 619 38

We evaluated whether assay of tissue polypeptide antigen (TPA) in sera is valuable for the determination of cancer stages compared to other tumor markers such as CEA, AFP, beta2-microglobulin, ferritin, and elastase-1. The study population consisted of cancer patients (33 gastric cancers, 7 colo-rectal cancers and 15 hepatomas), 169 patients with benign gastro-enteric diseases and 72 healthy volunteers. The percentage of positive cases for TPA (higher than 200 u/l) was 61% in gastric cancer, 71% in colo-rectal cancer and 87% in hepatoma. In certain non-cancerous conditions, such as gastric ulcer (active stage), acute hepatitis and chronic hepatitis, the TPA levels were increased over the level of healthy volunteers. There was no significant correlation between TPA and the other tumor markers. Our study suggests that TPA may be useful in the identification and evaluation of cancer patients.
 ...
PMID:[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]. 620 29

We succeeded in an establishment of a human pancreatic cancer cell line (PK-1) from liver metastasis of pancreatic cancer. Primary pancreatic cancer cells grew as islands surrounded by fibroblastic cells. However, these fibroblastic cells were gradually omitted by the polygonal shaped cancer cells. This cell line contained neither zymogen granules nor trypsin indicating that this pancreatic cancer originated from pancreatic duct cells. Modal chromosome numbers of this cell line were 42 and 72 and the doubling time was 48 hr. This cell line was transplantable in athymic nude mice to form progressive tumors which had histology similar to that of the original cancer (papillotubular adenocarcinoma). Neither AFP nor ferritin but CEA was detected on the surface and in the cytoplasm of this cell line in indirect immunofluorescence. Rabbit antiserum against this pancreatic cancer cell line detected pancreatic cancer associated antigen besides CEA in the culture supernatant. This antiserum reacted with sera from patients with pancreatic cancer to form a distinct precipitin line in agarose gel which fused with the precipitin line formed between the culture supernatant of this cell line and the antiserum.
 ...
PMID:Establishment of a human pancreatic cancer cell line and detection of pancreatic cancer associated antigen. 620 69

Pancreatic oncofetal antigen (POA) is considered to be an oncofetal antigen for human pancreas, and its measurement seems to be useful in the diagnosis of pancreatic cancer. In this study, POA, CEA, ferritin, BMG (beta 2 microglobulin) and AFP either in sera in pancreatic juice were measured in patients with pancreatic cancer, chronic pancreatitis and other various diseases, and their diagnostic value was comparatively evaluated. POA showed the highest sensitivity for pancreatic cancer compared with CEA or others. POA and CEA in pancreatic juice showed higher sensitivity and specificity than those in serum, probably reflecting the earlier malignant status. Localization of POA was immunohistochemically observed in tissues of pancreatic cancer and fetal pancreas. In some cases of pancreatic cancer with elevated serum CEA, ferritin and BMG, only CEA was positive in cancer cells, indicating that CEA is produced from cancer cells while ferritin and BMG are not produced from them. The combined assay of POA and CEA improved sensitivity for the diagnosis of pancreatic cancer. It is concluded that POA could be a useful tumor marker providing valuable information in the clinical diagnostic system of pancreatic cancer.
 ...
PMID:[Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer]. 634 42

Serum ferritin levels in patients with gynecological malignancy were measured by radioimmunoassay and in addition CEA, AFP and CRP were measured simultaneously. No samples had elevated values more than 200 ng/ml in none malignancy. The serum ferritin levels was elevated (greater than 200 ng/ml) in many patients with advanced cervical cancer and its recurrence, while early stage were almost within normal ferritin range. Patients with ovarian cancer showed normal ferritin levels, but its recurrence showed almost within normal levels than other groups. Serial measurements of serum ferritin showed a fall in patients who responded to radiation therapy or chemotherapy. In patients with tumor progression during therapy, ferritin values increased. The highest ferritin levels were found in patients with the time of recurrence and death. Ferritin levels showed low values in 5 cases of ovarian cancer without symptoms of recurrence on follow-up over 18 months. No correlation was found between ferritin and CEA or AFP levels in different patients except some cases. These results suggest that determination of serum ferritin may be useful to detect recurrence and to monitor the result of treatment.
 ...
PMID:[Serum ferritin levels in patient with gynecological malignancy--especially the judgement of therapeutic response and the monitor during the post-therapeutic follow-up period (author's transl)]. 731 Jan 97

We report of a 39 years old patient with a large testicular tumor found during an examination for infertility. The tumor consisted of a spermatocytic seminoma (SS) and a differentiated teratoma (TD). Furthermore, two small foci of seminoma were seen in the surrounding testicular tissue, several testicular tubuli contained carcinoma in situ (CIS). The diagnosis was based on the results obtained with various immunohistochemical markers: keratin, vimentin, desmin, LCA, CD3, CD20, CD45R, ferritin, PLAP, AFP. On the basis of the macroscopic and histopathological features, we propose the following etiology: CIS progressed in an earlier phase to the (larger) TD and later to the (smaller) classical seminoma; likewise, in an earlier phase, SS developed from a still unknown precursor stage. Our case of a mixed tumor as well as other cases reported in the last years do not allow the explanation of a differing etiology for SS. On the contrary, it may be presumed that the origins of seminoma and teratoma on the one hand and SS on the other hand are less divergent than hitherto thought.
 ...
PMID:[A combination of spermatocytic and classic seminoma, mature teratoma and carcinoma in situ of the testis. An attempt at an etiologic explanation]. 821 26

The ES 300 system, a fully automated multichannel immunoassay analyzer, was evaluated simultaneously for 9 weeks in four major centers. Precision, accuracy, carryover, comparison to in-house methods, and interferences were assessed for the following 17 tests: T4, T3, FT4, TSH, TBK, TBG, LH, FSH, prolactin, HCG, digoxin, cortisol, ferritin, IgE, insulin, AFP, and CEA. All centers reported good intra-lab and inter-lab precision. Accuracy was judged to be good based on correlation with in-house methods and recovery of target values in commercial and proficiency control materials. Linearity was evaluated for 14 analytes. Method biases were observed for T3 and insulin that were attributed to differences in standardization. No significant interferences from bilirubin, lipemia, and hemolysis were observed for all methods except insulin and AFP. Featuring random access capability, low daily maintenance, and high throughput, the ES 300 system performed well and met the stated claims of the manufacturer.
 ...
PMID:A multicenter evaluation of the Boehringer Mannheim ES 300 immunoassay system. 844 40

This paper deals with the organization, the data processing and some of the results obtained in Italian external quality assessment (EQA) schemes for hormones, tumor markers and hepatitis B markers. The EQA for hormones and tumor markers includes up to sixteen analytes together with the participation, in 1990, of about 250 laboratories. Laboratory results were used to prepare periodic and end-of-period reports. The former includes the results (with the related statistical parameters) obtained by all participants and by laboratories using the same method, as well as the histogram of the data. The end-of-period report contains estimates of imprecision and average bias for all laboratories, for each laboratory and for the more widely employed kits. From 1980 to 1988, laboratory variability improved significantly for TSH, progesterone, estradiol, testosterone, CEA and ferritin, slightly for cortisol, FSH, prolactin and AFP, while there was no improvement for both total T3 and T4. For LH we found an unusually high variability mainly due to systematic differences between kits based on different monoclonal antibodies. About 200 laboratories participated in the EQA for hepatitis B markers (HBsAg and anti-HBs) organized in 1990. For these analytes the periodic reports show the percentage of negative and positive results and the histogram of the responses (absorbance or counts) normalized with respect to the cut off.
 ...
PMID:Italian external quality assessment scheme in immunoassay. 854 60


<< Previous 1 2 3 4 5 Next >>